SCHEMBL11945892

SCHEMBL11945892

COc1cc(CNS(=O)(=O)N2CCN(c3cnn(-c4ccccc4)c(=O)c3OCC3(C)CC3)CC2)ccc1N

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.41
▸ ALDH1A1 P00352 5/20 0.39
▸ DCTPP1 Q9H773 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.36
▸ PPARG P37231 1/20 0.36
▸ NR2E3 Q9Y5X4 1/20 0.36
▸ NCOR2 Q9Y618 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ MCL1 Q07820 1/20 0.34
▸ SLC2A1 P11166 7/20 0.34
▸ SLC2A3 P11169 7/20 0.34
▸ SLC2A2 P11168 4/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945893 0.95 MAPT (0.40) MAPTALDH1A1DCTPP1NPSR1PPARG
SCHEMBL11945870 0.93 NPSR1 (0.41) MAPTALDH1A1DCTPP1NPSR1PPARG
SCHEMBL11945894 0.88 NPSR1 (0.41) MAPTALDH1A1DCTPP1NPSR1PPARG
SCHEMBL11945911 0.87 POLB (0.42) MAPTALDH1A1DCTPP1NPSR1PPARG
SCHEMBL11945926 0.84 POLB (0.42) MAPTALDH1A1DCTPP1NPSR1PPARG
SCHEMBL11945951 0.84 POLB (0.46) MAPTALDH1A1DCTPP1NPSR1PPARG
SCHEMBL17058593 0.84 MAPT (0.45) MAPTALDH1A1DCTPP1NPSR1PPARG
SCHEMBL11945958 0.84 POLB (0.45) MAPTALDH1A1DCTPP1NPSR1PPARG
SCHEMBL11945927 0.84 POLB (0.42) MAPTALDH1A1DCTPP1NPSR1PPARG
SCHEMBL11945945 0.83 POLB (0.40) MAPTALDH1A1DCTPP1NPSR1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885ALDH1A1 2437/4885DCTPP1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback